Inclusion Criteria:

          1. Previously untreated and pathologically confirmed, surgically resectable Stage IA3,
             IB, II, or IIIA NSCLC of squamous or non-squamous histology.

          2. ≥1 radiologically measurable tumor >2cm in diameter.

          3. Smoking history ≥10 pack years.

          4. Available tissue block for analysis from a core needle biopsy(or similar sample)

          5. High-sensitivity C-reactive protein (hsCRP) level ≥2 mg/L

        Exclusion Criteria:

          1. Any prior exposure to chemotherapy, radiotherapy or systemic anti-cancer therapy
             (e.g., monoclonal antibody therapy) for lung cancer.

          2. Malignancies other than NSCLC within 2 years prior to Cycle 1, Day 1, with the
             exception of those with a negligible risk of metastasis or death and with expected
             curative outcome

          3. Currently participating in, or has participated in, a trial of an investigational
             agent within 4 weeks prior to the first dose of study treatment or 5 half-lives,
             whichever is longer and with recovery of clinically significant toxicities from that
             therapy.

          4. Tumors known to express driver mutations of the EGFR or ALK pathways.

          5. Known severe hypersensitivity (Grade ≥3) to FL-101, its active substance, or any of
             its excipients

          6. Known history of human immunodeficiency virus or active Hepatitis B or Hepatitis C
             infection

        Additional Exclusion Criteria for Patients with Stage II and III Disease

          1. Prior treatment with anti-PD-1, anti-CTLA-4, or anti-PD-L1 therapeutic antibody or
             pathway-targeting agents

          2. Treatment with systemic immunosuppressive medications (including but not limited to
             prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor
             necrosis factor [anti-TNF] agents) within 2 weeks prior to Cycle 1, Day 1

          3. Known severe hypersensitivity (Grade ≥3) to nivolumab or chemotherapy agents or to any
             of their excipients.